Analysts Are Pretty Bullish … Surface Oncology (NASDAQ:SURF)

Earnings results for Surface Oncology (NASDAQ:SURF)

Surface Oncology, Inc. is estimated to report earnings on 11/10/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.41. The reported EPS for the same quarter last year was $-0.61.

Surface Oncology last announced its quarterly earnings data on August 11th, 2020. The reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.02. Surface Oncology has generated ($1.97) earnings per share over the last year. Surface Oncology has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 10th, 2020 based off prior year’s report dates.

Analyst Opinion on Surface Oncology (NASDAQ:SURF)

4 Wall Street analysts have issued ratings and price targets for Surface Oncology in the last 12 months. Their average twelve-month price target is $10.67, predicting that the stock has a possible upside of 22.32%. The high price target for SURF is $12.00 and the low price target for SURF is $9.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Surface Oncology has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $10.67, Surface Oncology has a forecasted upside of 22.3% from its current price of $8.72. Surface Oncology has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Surface Oncology (NASDAQ:SURF)

Surface Oncology does not currently pay a dividend. Surface Oncology does not have a long track record of dividend growth.

Insiders buying/selling: Surface Oncology (NASDAQ:SURF)

In the past three months, Surface Oncology insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,200.00 in company stock. Only 35.00% of the stock of Surface Oncology is held by insiders. 55.59% of the stock of Surface Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Surface Oncology (NASDAQ:SURF

Earnings for Surface Oncology are expected to decrease in the coming year, from ($0.72) to ($1.65) per share. The P/E ratio of Surface Oncology is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Surface Oncology is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Surface Oncology has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here